"DNA Topoisomerases, Type II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex.
Descriptor ID |
D004250
|
MeSH Number(s) |
D08.811.399.403.741
|
Concept/Terms |
DNA Topoisomerases, Type II- DNA Topoisomerases, Type II
- Type II DNA Topoisomerase
- Topoisomerase II
- DNA Topoisomerase (ATP-Hydrolysing)
- DNA Topoisomerase II
- DNA Type 2 Topoisomerase
|
Below are MeSH descriptors whose meaning is more general than "DNA Topoisomerases, Type II".
Below are MeSH descriptors whose meaning is more specific than "DNA Topoisomerases, Type II".
This graph shows the total number of publications written about "DNA Topoisomerases, Type II" by people in this website by year, and whether "DNA Topoisomerases, Type II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 0 | 2 | 2 |
1999 | 2 | 1 | 3 |
2000 | 0 | 2 | 2 |
2004 | 0 | 1 | 1 |
2005 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "DNA Topoisomerases, Type II" by people in Profiles.
-
Preliminary safety evaluation of the putative cancer chemopreventive agent tricin, a naturally occurring flavone. Cancer Chemother Pharmacol. 2006 Jan; 57(1):1-6.
-
Emergence of translocation t(9;11)-positive leukemia during treatment of childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2004 Nov; 41(3):291-6.
-
Development of resistance to ciprofloxacin, rifampin, and mupirocin in methicillin-susceptible and -resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2000 Nov; 44(11):3229-31.
-
Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season. Antimicrob Agents Chemother. 2000 Feb; 44(2):462-6.
-
Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. FEMS Immunol Med Microbiol. 1999 Dec; 26(3-4):281-7.
-
Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones. Antimicrob Agents Chemother. 1999 Oct; 43(10):2513-6.
-
Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins. Antimicrob Agents Chemother. 1999 Aug; 43(8):2051-5.
-
Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC. Antimicrob Agents Chemother. 1998 May; 42(5):1249-52.
-
Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 1998 Apr; 41(4):481-4.
-
Kinetics of nuclear translocation and turnover of the vitamin D receptor in human HL60 leukemia cells and peripheral blood lymphocytes--coincident rise of DNA-relaxing activity in nuclear extracts. J Steroid Biochem Mol Biol. 1992 Mar; 42(1):11-6.